Pharmacokinetics of NESP in Cancer Patients
Author Information
Author(s): Heatherington A C, Schuller J, Mercer A J
Primary Institution: Amgen Inc
Hypothesis
The study evaluates the pharmacokinetic profile of NESP in patients receiving multiple cycles of chemotherapy.
Conclusion
NESP was well tolerated and may allow for less frequent dosing while improving anaemia in cancer patients.
Supporting Evidence
- NESP has a 3-fold greater half-life compared to rHuEPO.
- Patients received NESP weekly for 3 cycles of chemotherapy.
- Pharmacokinetic parameters were measured after the first and third chemotherapy cycles.
Takeaway
This study looked at a new treatment for anemia in cancer patients and found it works well and might not need to be given as often as other treatments.
Methodology
Anaemic patients received NESP weekly during chemotherapy, with blood samples collected for pharmacokinetic analysis.
Limitations
The subjects for whom all parameters could be calculated may represent a sub-group of the entire population.
Participant Demographics
Anaemic patients with non-myeloid malignancies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website